Bevacizumab: overview of the literature.

  title={Bevacizumab: overview of the literature.},
  author={Maria Ignez F. Braghiroli and Jorge Sabbaga and Paulo Marcelo Gehm Hoff},
  journal={Expert review of anticancer therapy},
  volume={12 5},
Inhibiting the angiogenic process is a clever method of cancer care. Over the last decade, some antiangiogenic compounds have been developed and approved for cancer treatment. Bevacizumab is a humanized monoclonal antibody that inhibits VEGF activity. When used in combination with chemotherapy, it has an important role for treating many types of advanced cancer, including colorectal cancer, renal cell carcinoma, non-small-cell lung cancer, breast cancer, ovarian cancer and glioblastoma… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 33 extracted citations


Publications referenced by this paper.
Showing 1-10 of 100 references

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011

Similar Papers

Loading similar papers…